Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

This study is currently recruiting participants.
Verified November 2013 by M.D. Anderson Cancer Center
Sponsor:
Collaborator:
Cyclacel Pharmaceuticals, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01253460
First received: December 1, 2010
Last updated: November 18, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)